Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China and internationally. It offers Ganovo, a direct-acting anti-viral agent for the treatment of hepatitis C virus (HCV); Pegasys, a pegylated interferon for Hepatitis B and C virus; and Ravidasvir, a pan-genotypic NS5A inhibitor for the treatment of HCV. Its products pipeline includes ASC22, a PD-L1 single domain antibody fragment crystallizable fusion, which is in Phase II trial for the treatment of chronic Hepatitis B infection; ASC40, a Phase II-ready fatty acid synthase inhibitor for the treatment of non-alcoholic steatohepatitis (NASH); and ASC41, an oral THR-Ã agonist for the treatment of NASH. The company's products also comprise ASC09, a protease inhibitor that has completed Phase IIA clinical trial to treat human immunodeficiency virus type-1 infections; ASC06, which has completed Phase I clinical trial for treating liver cancer; and ASC21, a HCV NS5B polymerase inhibitor. In addition, it is developing therapies that are in pre-clinical trials for the treatment of hepatitis B virus and NASH. The company was incorporated in 2014 and is headquartered in Hangzhou, the People's Republic of China.
Read More
